Literature DB >> 32852669

Review of cancer-associated fibroblasts and their microenvironment in post-chemotherapy recurrence.

Genichiro Ishii1,2, Takahiro Ishii3,4,5.   

Abstract

Cancer tissue comprises not only cancer cells, but also several types of non-cancerous cells, such as cancer-associated fibroblasts. These fibroblasts directly and/or indirectly communicate with the cancer cells and other types of stromal cells, to create a specific tumor microenvironment. Cytotoxic chemotherapy plays a central role in treating cancer; however, tumor re-progression (recurrence) is a significant problem for cancer patients. Cytotoxic anticancer drugs act on fibroblasts as well as cancer cells and, after chemotherapy, all surviving cells are in contact with one another in the local environment. Therefore, an understanding of the molecular interactions between surviving cancer cells and fibroblasts is necessary to prevent tumor re-progression and to sustain the effect of cytotoxic agents. After chemotherapy, the number of fibroblasts may increase, some of which are identifiable as tumor-promoting. In this review, we discuss the significance of cancer-associated fibroblasts in tumor re-progression after chemotherapy, and the potential value of targeting them to enhance clinical outcomes.

Entities:  

Keywords:  Cancer-associated fibroblasts; Post chemotherapy; Tumor microenvironment; Tumor re-progression

Mesh:

Substances:

Year:  2020        PMID: 32852669     DOI: 10.1007/s13577-020-00417-8

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.174


  46 in total

Review 1.  Phenotypic and functional heterogeneity of cancer-associated fibroblast within the tumor microenvironment.

Authors:  Genichiro Ishii; Atsushi Ochiai; Shinya Neri
Journal:  Adv Drug Deliv Rev       Date:  2015-08-14       Impact factor: 15.470

2.  Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer.

Authors:  Y Yamada; K Higuchi; K Nishikawa; M Gotoh; N Fuse; N Sugimoto; T Nishina; K Amagai; K Chin; Y Niwa; A Tsuji; H Imamura; M Tsuda; H Yasui; H Fujii; K Yamaguchi; H Yasui; S Hironaka; K Shimada; H Miwa; C Hamada; I Hyodo
Journal:  Ann Oncol       Date:  2014-10-14       Impact factor: 32.976

3.  Podoplanin-positive fibroblasts enhance lung adenocarcinoma tumor formation: podoplanin in fibroblast functions for tumor progression.

Authors:  Ayuko Hoshino; Genichiro Ishii; Takashi Ito; Kazuhiko Aoyagi; Yoichi Ohtaki; Kanji Nagai; Hiroki Sasaki; Atsushi Ochiai
Journal:  Cancer Res       Date:  2011-05-24       Impact factor: 12.701

4.  Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion.

Authors:  Akira Orimo; Piyush B Gupta; Dennis C Sgroi; Fernando Arenzana-Seisdedos; Thierry Delaunay; Rizwan Naeem; Vincent J Carey; Andrea L Richardson; Robert A Weinberg
Journal:  Cell       Date:  2005-05-06       Impact factor: 41.582

Review 5.  Fibroblasts in cancer.

Authors:  Raghu Kalluri; Michael Zeisberg
Journal:  Nat Rev Cancer       Date:  2006-05       Impact factor: 60.716

6.  Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation.

Authors:  Tatsuya Yoshida; Genichiro Ishii; Koichi Goto; Shinya Neri; Hiroko Hashimoto; Kiyotaka Yoh; Seiji Niho; Shigeki Umemura; Shingo Matsumoto; Hironobu Ohmatsu; Shinsuke Iida; Akio Niimi; Kanji Nagai; Yuichiro Ohe; Atsushi Ochiai
Journal:  Clin Cancer Res       Date:  2014-11-11       Impact factor: 12.531

7.  S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

Authors:  Wasaburo Koizumi; Hiroyuki Narahara; Takuo Hara; Akinori Takagane; Toshikazu Akiya; Masakazu Takagi; Kosei Miyashita; Takashi Nishizaki; Osamu Kobayashi; Wataru Takiyama; Yasushi Toh; Takashi Nagaie; Seiichi Takagi; Yoshitaka Yamamura; Kimihiko Yanaoka; Hiroyuki Orita; Masahiro Takeuchi
Journal:  Lancet Oncol       Date:  2008-02-20       Impact factor: 41.316

Review 8.  Carcinoma-associated fibroblasts: non-neoplastic tumour-promoting mesenchymal cells.

Authors:  Urszula M Polanska; Akira Orimo
Journal:  J Cell Physiol       Date:  2013-08       Impact factor: 6.384

9.  Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling.

Authors:  Pernilla Roswall; Matteo Bocci; Michael Bartoschek; Hong Li; Glen Kristiansen; Sara Jansson; Sophie Lehn; Jonas Sjölund; Steven Reid; Christer Larsson; Pontus Eriksson; Charlotte Anderberg; Eliane Cortez; Lao H Saal; Christina Orsmark-Pietras; Eugenia Cordero; Bengt Kristian Haller; Jari Häkkinen; Ingrid J G Burvenich; Elgene Lim; Akira Orimo; Mattias Höglund; Lisa Rydén; Holger Moch; Andrew M Scott; Ulf Eriksson; Kristian Pietras
Journal:  Nat Med       Date:  2018-03-12       Impact factor: 53.440

Review 10.  Cancer-associated fibroblasts as another polarized cell type of the tumor microenvironment.

Authors:  Martin Augsten
Journal:  Front Oncol       Date:  2014-03-27       Impact factor: 6.244

View more
  1 in total

1.  Cancer-associated fibroblast-derived exosomal microRNA-20a suppresses the PTEN/PI3K-AKT pathway to promote the progression and chemoresistance of non-small cell lung cancer.

Authors:  Lin Shi; Weiliang Zhu; Yuanyuan Huang; Lin Zhuo; Siyun Wang; Shaobing Chen; Bei Zhang; Bin Ke
Journal:  Clin Transl Med       Date:  2022-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.